ONCOmmunity

Vascular-Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Mid-Term Oncological Outcomes.

By: Souhil Lebdai, Pierre Bigot, Pierre-Adrien Leroux, Louis-Paul Berthelot, Pierre Maulaz, Abdel-Rahmene Azzouzi

Urology Department, University Hospital of Angers, Angers, FRANCE. Electronic address: souhil.lebdai@gmail.com.
2017-03-12; doi: 10.1016/j.juro.2017.03.119

Abstract

Purpose

To assess the mid-term oncological outcomes of vascular-targeted photodynamic therapy with padeliporfin for low-risk prostate cancer treatment.

Material

We prospectively assessed all patients treated with vascular-targeted photodynamic therapy for low-risk prostate cancer in our center. Patients were followed every 6 months. All patients underwent prostate biopsies 6 months post-treatment or in case of biological or clinical progression. Primary endpoint was the progression-free survival. Secondary endpoints were: absence of clinically significant cancer in the treated lobes, radical therapy occurrence and PSA rate. Variables were compared with chi-square or Mann-Whitney test or Wilcoxon tests; progression-free survival was reported with Kaplan-Meier curves.

Results

Eighty-two men were treated with vascular-targeted photodynamic therapy. Median follow-up was 68 months (6-89). Median progression-free survival was 86 months (95%CI: 82-90). Median PSA decreased significantly by 41% six months post-treatment and remained stable during the follow-up (p<0.001). A total of 115 lobes were treated; absence of clinically significant cancer was achieved in 82% (94/115) of the treated lobes. 24% (20/82) of the patients underwent radical therapy (18 radical prostatectomies, 2 brachytherapies) after a median time of 22 months (6-86). Limitations include: a single-armed design, population size and mid-term follow-up.

Conclusions

Padeliporfin vascular-targeted photodynamic therapy for low-risk prostate cancer treatment achieved an 82% absence of clinically significant cancer in the treated lobes and 76% of the patients avoided radical therapies with a median follow-up of 68 months. However, longer follow-up is required for long-term outcomes.